Catalyst Pharmaceuticals

Showing 4 posts of 4 posts found.

Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal

June 20, 2023
Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera

Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …


Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug

February 17, 2020
Research and Development, Sales and Marketing Bernie, Bernie Sanders, Catalyst Pharmaceuticals, FDA, TRUMP FDA, US FDA

Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders led to the approval of …


Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes

October 31, 2019
Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure

Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …


Sanders calls on Catalyst pharma to justify $375,000 price tag for rare disease drug which was once free

February 5, 2019
Manufacturing and Production Catalyst Pharmaceuticals, Jacobus Pharmaceuticals, Sanders, USA, pharma, pricing

Shares in Catalyst Pharmaceuticals plummeted Monday, after US Senator Bernie Sanders sent the firm a letter asking them to justify …

Latest content